144 related articles for article (PubMed ID: 30074574)
1. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
[TBL] [Abstract][Full Text] [Related]
2. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
3. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
[TBL] [Abstract][Full Text] [Related]
4. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
7. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
[TBL] [Abstract][Full Text] [Related]
8. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.
Siggaard CB; Kazankov K; Rødgaard-Hansen S; Møller HJ; Donnelly MC; Simpson KJ; Grønbaek H
Scand J Gastroenterol; 2019 May; 54(5):623-632. PubMed ID: 31067143
[TBL] [Abstract][Full Text] [Related]
9. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
[TBL] [Abstract][Full Text] [Related]
10. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
Kimer N; Gudmann NS; Pedersen JS; Møller S; Nielsen MJ; Leeming DJ; Karsdal MA; Møller HJ; Bendtsen F; Grønbæk H
PLoS One; 2018; 13(9):e0203200. PubMed ID: 30183743
[TBL] [Abstract][Full Text] [Related]
11. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease.
De Vito R; Alisi A; Masotti A; Ceccarelli S; Panera N; Citti A; Salata M; Valenti L; Feldstein AE; Nobili V
Int J Mol Med; 2012 Jul; 30(1):49-56. PubMed ID: 22505182
[TBL] [Abstract][Full Text] [Related]
12. Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with non‑alcoholic fatty liver disease.
Schwenger KJP; Chen L; Chelliah A; Da Silva HE; Teterina A; Comelli EM; Taibi A; Arendt BM; Fischer S; Allard JP
Int J Mol Med; 2018 Oct; 42(4):2229-2237. PubMed ID: 30085339
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
[TBL] [Abstract][Full Text] [Related]
14. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.
Björklund J; Laursen TL; Sandahl TD; Møller HJ; Vilstrup H; Ott P; Grønbæk H
Orphanet J Rare Dis; 2018 Sep; 13(1):169. PubMed ID: 30241550
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.
Bossen L; Rebora P; Bernuzzi F; Jepsen P; Gerussi A; Andreone P; Galli A; Terziroli B; Alvaro D; Labbadia G; Aloise C; Baiocchi L; Giannini E; Abenavoli L; Toniutto P; Marra F; Marzioni M; Niro G; Floreani A; Møller HJ; Valsecchi MG; Carbone M; Grønbaek H; Invernizzi P
Liver Int; 2020 Jun; 40(6):1408-1414. PubMed ID: 32279422
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
17. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
Andersen MN; Andersen NF; Rødgaard-Hansen S; Hokland M; Abildgaard N; Møller HJ
Leuk Res; 2015 Sep; 39(9):971-5. PubMed ID: 26169445
[TBL] [Abstract][Full Text] [Related]
18. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation.
Maurice JB; Garvey L; Tsochatzis EA; Wiltshire M; Cooke G; Guppy N; McDonald J; Marchesi J; Nelson M; Kelleher P; Goldin R; Thursz M; Lemoine M
AIDS; 2019 Apr; 33(5):805-814. PubMed ID: 30882489
[TBL] [Abstract][Full Text] [Related]
19. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
[TBL] [Abstract][Full Text] [Related]
20. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.
Glavind E; Gotthardt DN; Pfeiffenberger J; Sandahl TD; Bashlekova T; Willemoe GL; Hasselby JP; Weiss KH; Møller HJ; Vilstrup H; Lee WM; Schilsky ML; Ott P; Grønbæk H
Orphanet J Rare Dis; 2020 Jul; 15(1):173. PubMed ID: 32615997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
